Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Cash from Financing Activities: 2023-2025

Historic Cash from Financing Activities for Artiva Biotherapeutics (ARTV) over the last 1 years, with Sep 2025 value amounting to -$37,000.

  • Artiva Biotherapeutics' Cash from Financing Activities fell 100.02% to -$37,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $100,000, marking a year-over-year change of. This contributed to the annual value of $162.2 million for FY2024, which is 565.11% up from last year.
  • According to the latest figures from Q3 2025, Artiva Biotherapeutics' Cash from Financing Activities is -$37,000, which was up 48.61% from -$72,000 recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Cash from Financing Activities high stood at $163.9 million for Q3 2024, and its period low was -$72,000 during Q2 2025.
  • For the 3-year period, Artiva Biotherapeutics' Cash from Financing Activities averaged around $26.9 million, with its median value being $239,000 (2025).
  • Within the past 5 years, the most significant YoY rise in Artiva Biotherapeutics' Cash from Financing Activities was 599.38% (2024), while the steepest drop was 103.12% (2024).
  • Artiva Biotherapeutics' Cash from Financing Activities (Quarterly) stood at $962,000 in 2023, then plummeted by 103.12% to -$30,000 in 2024, then plummeted by 100.02% to -$37,000 in 2025.
  • Its last three reported values are -$37,000 in Q3 2025, -$72,000 for Q2 2025, and $239,000 during Q1 2025.